## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.1% below STRENGTH zone (4.0-10.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($52.24)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Robeco Institutional Asset Management B.V. Acquires 409,231 Shares of Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20260106T115958 | Bullish | Relevance: 100%
- Robeco Institutional Asset Management B.V. has increased its stake in Bristol Myers Squibb Company ($BMY) by 6.4%, acquiring an additional 409,231 shares during the 3rd quarter. This brings their total holdings to 6,810,632 shares, valued at $307.16 million, representing 0.33% of the company. Other institutional investors also adjusted their positions in BMY, which recently announced a quarterly dividend increase.

**2. KG&L Capital Management LLC Has $1.07 Million Stock Holdings in Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20260106T110743 | Somewhat-Bullish | Relevance: 100%
- KG&L Capital Management LLC significantly reduced its stake in Bristol Myers Squibb (BMY) by 49.4%, now holding 23,599 shares valued at $1.07 million. Despite this reduction, Bristol Myers Squibb delivered strong Q3 results, beating EPS and revenue estimates, and announced an increased quarterly dividend to $0.63, with institutional ownership remaining high at 76.41%. Analyst consensus currently rates BMY as "Hold" with a target price of $54.62.

**3. Bristol Myers Squibb Company $BMY Position Decreased by D.A. Davidson & CO.**
- Source: MarketBeat | 20260106T092905 | Neutral | Relevance: 100%
- D.A. Davidson & CO. has significantly reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 22.7%, selling 78,288 shares and retaining 266,519 shares valued at approximately $12.02 million. This comes as Bristol Myers Squibb increased its quarterly dividend to $0.63, yielding around 4.7%, and analysts maintain a consensus "Hold" rating with a $54.62 price target. The company recently reported quarterly earnings that topped estimates and issued FY 2025 guidance.

**4. Railway Pension Investments Ltd Purchases 40,300 Shares of Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20260105T123008 | Somewhat-Bullish | Relevance: 100%
- Railway Pension Investments Ltd increased its stake in Bristol Myers Squibb (BMY) by 3.7% in Q3, purchasing an additional 40,300 shares, bringing its total holdings to 1,139,600 shares valued at approximately $51.4 million. The biopharmaceutical company recently exceeded its Q3 earnings and revenue estimates and raised its quarterly dividend to $0.63 per share, representing an annualized yield of 4.7%. Despite a consensus "Hold" rating from analysts, institutional investors now own about 76.4% of the stock.

**5. Motley Fool: Fat dividend and a chance for growth**
- Source: The Spokesman-Review | 20260104T140805 | Bullish | Relevance: 100%
- Bristol Myers Squibb (NYSE: BMY) presents a compelling investment opportunity despite recent modest revenue growth and upcoming patent expirations. The company has successfully launched new products like Opdualag, Breyanzi, and Camzyos, and has a robust drug pipeline. With a forward-looking P/E ratio significantly below the sector average, it could appeal to long-term dividend investors.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +8%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (3 raises, avg +8%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.8B |
| Beta | 0.29 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 9.1 |
| Current P/E | 8.3 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 2.1% (minimal 5-day change). Below STRENGTH zone by 1.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.15% (CS: 60) | Neutral |
| RSI_14 | 63.3 | Neutral |
| MACD Histogram | -0.26 | Bearish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.096x | Above |
| vs SMA200 | 1.124x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $54.46
- **Stop Loss:** $52.24 (4.1% risk)
- **Target:** $56.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 594
- **Position Value:** $32,349.24
- **Portfolio %:** 32.35%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*